Risk of new-onset neovascular age-related macular degeneration in patients with diabetes more than doubles with use of glucagon-like peptide-1 receptor agonists for 6 months.
All you need to know about the current spectrum of injectable therapies in diabetes care. Understand the types, mechanisms, efficacy, and safety of insulin and non-insulin injections, with a focus on optimizing outcomes.
In patients with chronic kidney disease and type 2 diabetes, finerenone plus empagliflozin combination therapy outperforms either monotherapy for UACR reduction.
Explore biomarker screening approaches to identifying pancreatic ductal adenocarcinoma in people with diabetes, screening in high-risk groups, and practical strategies for early identification and monitoring.
Anatomical and physiological changes with obesity contribute to the development of GERD. Explore how obesity also impacts its diagnosis and management, and the need to look beyond conventional treatments.
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Metabolic disorders, like hyperlipidemia and diabetes, are high-risk factors for developing retinal artery occlusion. Timely intra-arterial thrombolysis in this case was crucial for preserving the patient's vision.
A 51-year-old man presented with severe generalized pain. Raised HbA1c and blood glucose levels, plus findings of pre-proliferative diabetic retinopathy, led to a diagnosis of type 2 diabetes and diabetic polyneuropathy.
A 64-year-old man with type 1 diabetes presented with notable abdominal swelling over the previous 3 months. Investigations led to a diagnosis of pseudoascites and celiac disease was identified as the cause.
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
Youth-onset metabolic diseases, including obesity and type 1 and type 2 diabetes, and their associated cardiometabolic complications represent a major global health challenge. The incidence and prevalence of these conditions vary across regions …
Neurology and Preclinical Neurological Studies - Review Article
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of multifaceted nature and variable progression that poses considerable challenges to our understanding of its evolution and interplay with different comorbid conditions. The …
Type 2 diabetes mellitus (T2DM) is a global health priority, with an estimated 629 million people projected to be affected by the year 2045. T2DM significantly increases the risk of atherosclerotic cardiovascular disease and other complications.
“Ozempic face” and facial aging have been observed as side effects in many patients after glucagon like peptide 1 receptor agonists (GLP-1RA) therapy for type 2 diabetes mellitus (T2DM) and obesity. However, those medications can reduce systemic …
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Treating children with hormone disorders is complex and requires tailored management. To help you provide the most effective care, we deliver resources covering adrenal, thyroid, pituitary, growth, and puberty disorders, obesity, and diabetes.
Type 2 diabetes mellitus (T2DM) has emerged as a major public health challenge in India, with over 100 million individuals currently affected and projections indicating a rise to 124 million by 2045 [ 1 ]. Despite the availability of effective …
Childhood overweight or obesity is a significant global health concern, with its prevalence having increased dramatically across all world regions in recent decades [ 1 ]. In particular, east Asia has experienced one of the largest absolute …
The occurrence of brain metastases (BM) is a prevalent and severe complication of cancer, impacting approximately 30% of patients diagnosed with malignant tumors [ 1 , 2 ]. As life expectancy continues to increase and cancer survivorship improves …
Obesity is a major risk factor for type 2 diabetes (T2D) and is prevalent in patients with T2D [ 1 ]. Moreover, obesity prevalence has increased in Finland [ 2 ], and the progression of T2D complications increases with continuous weight gain [ 3 ].
Risk of new-onset neovascular age-related macular degeneration in patients with diabetes more than doubles with use of glucagon-like peptide-1 receptor agonists for 6 months.
Risk of new-onset neovascular age-related macular degeneration in patients with diabetes more than doubles with use of glucagon-like peptide-1 receptor agonists for 6 months.
In patients with chronic kidney disease and type 2 diabetes, finerenone plus empagliflozin combination therapy outperforms either monotherapy for UACR reduction.
The GRI was proposed as a composite metric that integrates both hypoglycemia and hyperglycemia episodes and is based on CGM data. What do we know so far about its benefits and limitations in people with type 1 or 2 diabetes?
